SR9009 acts as a promising therapeutic agent against PCS1, the most lethal prostate cancer subtype, by modulating the LXRα/FOXM1 pathway independently of REV-ERBs. This pathway is crucial for cell proliferation and survival in aggressive prostate cancers. SR9009 effectively inhibits FOXM1-related gene expression, including CCNB1, CDK1, and BIRC5, which are highly expressed in PCS1 tumors. Experimental models reveal its efficacy in reducing tumor size and halting cancer progression without affecting normal prostate cells. SR9009 impedes cancer cell migration, disrupts the cell cycle, and promotes apoptosis, addressing key hallmarks of malignancy. Importantly, it bypasses androgen receptor-dependent mechanisms, offering a viable treatment for advanced and resistant prostate cancers. This makes SR9009 a novel, selective therapy for PCS1 prostate cancer.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Stenobolic by Driada Medical, consult with your doctor or healthcare professional.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.
Home
